Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 3Unknown 2Terminated 2Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 41Thoracic 17Head & Neck 8Lymphoid 4Tumor-Agnostic 3Genitourinary 3Other solid neoplasm 2Gynecologic 2CNS 2Breast 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Standard of Care 4Radiotherapy 4Oxaliplatin 4tislelizumab 3anlotinib 2Radiation 2Paclitaxel 2Capecitabine 2130-nm albumin-bound paclitaxel 2vedolizumab 1trastuzumab deruxtecan 1trametinib 1toripalimab 1surufatinib 1pembrolizumab 1ivosidenib 1disitamab vedotin 1coenzyme Q10 1cemiplimab 1blinatumomab 1Whole Genome Sequencing 1Ursodeoxycholic Acid 1Ultrasonography 1Tretinoin 1Thymopentin 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Respiratory Rate 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × tislelizumab × Tumor-Agnostic × Clear all
NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
752 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07348107 2026-01-16

ATARI-PDAC

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 1 Not yet recruiting
10 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Shanghai Chest Hospital

Phase 1/2 Not yet recruiting
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡